Vaccination against cytomegalovirus

  • S. A. Plotkin
Conference paper


Like varicella zoster virus (VZV), human cytomegalovirus (HCMV) causes disease after both primary and recurrent infections. The former is more serious, particularly in pregnant women, who may transmit the virus to their offspring, with a high risk of mental retardation and deafness. Various experimental vaccines are in development, ranging from live, attenuated HCMV, subunit envelope glycoprotein, poxvirus vectors with CMV genes inserted, and plasmid DANN.


Human Cytomegalovirus Induce Neutralize Antibody Congenital Cytomegalovirus Infection Human Cytomegalovirus Infection Poxvirus Vector 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Adler SP (1996) Current prospects for immunization against cytomegaloviral disease. Infect Agents Dis 5: 29–35PubMedGoogle Scholar
  2. 2.
    Adler SP (1986) Molecular epidemiology of cytomegalovirus: evidence for viral transmission to parents from children infected at a day care center. Pediatr Infect Dis 5: 315–318PubMedCrossRefGoogle Scholar
  3. 3.
    Adler SP, Hempfling SH, Starr SE, Plotkin SA, Riddell S (1998) Safety and immunogenicity of the Towne strain cytomegalovirus vaccine. Pediatr Infect Dis J 17: 200–206PubMedCrossRefGoogle Scholar
  4. 4.
    Adler SP, Plotkin SA, Gonczol E, Cadoz M, Meric C, Wang JB, Dellamonica P, Best AM, Zahradnik J, Pincus S, Berencsi K, Cox WI, Gyulai Z (1999) A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J Infect Dis 180: 843–846PubMedCrossRefGoogle Scholar
  5. 5.
    Adler SP, Starr SE, Plotkin SA, Hempfling SH, Buis J, Manning ML, Best AM (1995) Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 171: 26–32PubMedCrossRefGoogle Scholar
  6. 6.
    Adler SP, Hempfling SH, Starr SE, Plotkin SA, Riddell S (1998) Safety and immunogenicity of the Towne strain cytomegalovirus vaccine. Pediatr Infect Dis 17: 200–206CrossRefGoogle Scholar
  7. 7.
    Balfour HH (1991) Prevention of cytomegalovirus disease in renal allograft recipients. Scand J Infect Dis 78: 88–93Google Scholar
  8. 8.
    Bennink JR, Yewdell JW, Smith GL, Moller C, Moss B (1984) Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells. Nature 311: 578–579PubMedCrossRefGoogle Scholar
  9. 9.
    Britt WJ, Mach M (1996) Human cytomegalovirus glycoproteins. Intervirology 39: 401–412PubMedGoogle Scholar
  10. 10.
    Burian K, Endresz V, Gyulai Z (1999) Prevalence of the IE1-exon4-specific CTL in naturally seropositive healthy individuals. [Abstract] 7th International Cytomegalovirus Workshop, Brighton, UK, March 7–9Google Scholar
  11. 11.
    Burke RL (1991) Development of a Herpes simplex virus subunit glycoprotein vaccine for prophylactic and therapeutic use. J Infect Dis 13: S906—S911CrossRefGoogle Scholar
  12. 12.
    Cha TA, Tom E, Kemble GW (1996) Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J Virol 70: 78–83PubMedGoogle Scholar
  13. 13.
    Chou SW (1986) Acquisition of donor strains of cytomegalovirus by renal-transplant recipients. N Engl J Med 314: 1418–1423PubMedCrossRefGoogle Scholar
  14. 14.
    Diamond DJ, York J, Sun JY, Wright CL, Forman SJ (1997) Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 90: 1751–1767PubMedGoogle Scholar
  15. 15.
    Elek SD, Stern H (1974) Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. Lancet 1: 1–5PubMedCrossRefGoogle Scholar
  16. 16.
    Endresz V, Kari L, Berencsi K, Kari C, Gyulai Z, Jeney C, Pincus S, Rodeck U, Meric C, Plotkin SA, Gonczol E (1999) Induction of human cytomegalovirus (HCMV)- glycoprotein B (gB)-specific neutralizing antibody and phosphorprotein 65 (pp65)- specific cytotoxic T lymphocyte responses by naked DNA immunization. Vaccine 17: 50–58PubMedCrossRefGoogle Scholar
  17. 17.
    Excler JL, Plotkin SA (1997) The prime-boost concept applied to HIV preventive vaccines. AIDS 11: S127—S137PubMedGoogle Scholar
  18. 18.
    Fox JC, Kidd IM, Griffiths PD, Sweny P, Emery VC (1995) Longitudinal analysis of cytomegalovirus load in renal transplant recipients using a quantitative polymerase chain reaction: correlation with disease. J Gen Virol 1995, 76: 309–319PubMedCrossRefGoogle Scholar
  19. 19.
    Fries LF, Tartaglia J, Taylor J, Kauffman EK, Meignier B, Paoletti E, Plotkin S (1996) Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Vaccine 14: 428–434PubMedCrossRefGoogle Scholar
  20. 20.
    Gonczol E, Berencsi K, Pincus S, Endresz V, Meric C, Paoletti E, Plotkin SA (1995) Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate. Vaccine 13: 1080–1085PubMedCrossRefGoogle Scholar
  21. 21.
    Gonczol E, lanocone J, Ho W, Starr S, Meignier B, Plotkin S (1990) Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers. Vaccine 8: 130–136PubMedCrossRefGoogle Scholar
  22. 22.
    Gratacap-Cavallier B, Bosson JL, Morand P, Dutertre N, Chanzy B, Jouk PS, Vandekerckhove C, Cart-Lamy P, Seigneurin JM (1998) Cytomegalovirus seroprevalence in French pregnant women. Eur J Epidemiol 14: 147–152PubMedCrossRefGoogle Scholar
  23. 23.
    Gupta R, Gonczol E, Manning ML, Starr S, Johnson B, Murphy GF, Plotkin SA (1993) Delayed type hypersensitivity to human cytomegalovirus. J Med Virol 39: 109–17PubMedCrossRefGoogle Scholar
  24. 24.
    Gyulai Z, Pincus S, Cox B (1999) Canarypox-CMV-pp65 recombinant immunization of seronegative subjects elicits pp65 specific CTL precursors with a frequency comparable to pp65 specific frequency of naturally seropositive individuals. [Abstract] 7th International Cytomegalovirus Workshop, Brighton, UK, March 7–9Google Scholar
  25. 25.
    Henderson DA, Moss B (1999) Smallpox. In: Plotkin SA, Orenstein WA (eds) Vaccines. W. B. Saunders, Philadelphia, pp 74–97Google Scholar
  26. 26.
    Keay S, Baldwin B (1991) Anti-idiotype antibodies that mimic gp86 of human cytomegalovirus inhibit viral fusion but not attachment. J Virol 65: 5124–5128PubMedGoogle Scholar
  27. 27.
    Krech U, Konjajev Z, Jung M (1971) Congenital cytomegalovirus infection in siblings from consecutive pregnancies. Hely Paediatr Acta 26: 355–362Google Scholar
  28. 28.
    Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR (1994) Recovery of HLArestricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83: 1971–1979PubMedGoogle Scholar
  29. 29.
    Liu H, Chou S, Sekulovich R, Duliege A-M, Burke RL (1997) A CMV glycoprotein gB subunit vaccine elicits cross neutralizing antibodies that cross neutralize clinical isolates. Abstract 43. Sixth International Cytomegalovirus Workshop. March 7–9, Perdido Beach, ALGoogle Scholar
  30. 30.
    Lucht E, Brytting M, Bjerregaard L (1998) Shedding of cytomegalovirus and herpesviruses.6,7, and 8 in saliva of human immunodeficiency virus type 1-infected patients and healthy controls. Clin Infect Dis 27: 137–141PubMedCrossRefGoogle Scholar
  31. 31.
    Magno A, Smith GL, Moss B (1982) Vaccinia virus. A selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci USA 79: 7415–7419Google Scholar
  32. 32.
    Marshall GS, Plotkin SA (1994) Progress toward developing a cytomegalovirus vaccine. Infect Dis Clinics N Am 4: 283–298Google Scholar
  33. 33.
    McLaughlin-Taylor E, Pande H, Forman SJ, Tanamachi B, Li CR, Zaia JA, Greenberg PD, Riddell SR (1994) Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol 43: 103–110PubMedCrossRefGoogle Scholar
  34. 34.
    Mitchell D, Holmes SJ, Burke RL, Sekulovich R, Tripathi M, Doyle M, Duliege AM (1997) Immunogenicity of a recombinant human cytomegalovirus (CMV) gB vaccine in toddlers. Sixth International Cytomegalovirus Workshop. March 5–9 (Abstract no. 50)Google Scholar
  35. 35.
    Mocarski ES Jr, Kemble GW (1996) Recombinant cytomegaloviruses for study of replication and pathogenesis. Intervirology 39: 320–330PubMedGoogle Scholar
  36. 36.
    Neff BJ, Weibel RE, Buynak EB, McAllen AA, Hillman MR (1979) Clinical and laboratory studies of live c cytomegalovirus vaccine Ad-169. Proc Soc Exp Biol Med 160: 32–37PubMedGoogle Scholar
  37. 37.
    Pande H, Campo K, Tanamachi B, Forman SJ, Zaia JA (1998) Direct DNA immunization of mice with plasmid DNA encoding the tegument protein pp65 (ppUL83) of human cytomegalovirus induces high levels of circulating antibody to the encoded protein. Scand J Infect Dis [Suppl] 99: 117–120Google Scholar
  38. 38.
    Panicali D, Paoletti E (1982) Construction of poxviruses as cloning vectores: Insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci USA 79: 4927–4931PubMedCrossRefGoogle Scholar
  39. 39.
    Pass RF, Hutto C, Ricks R, Cloud GA (1986) Increased rate of cytomegalovirus infection among parents of children attending day-care centers. N Engl J Med 314: 1414–1418PubMedCrossRefGoogle Scholar
  40. 40.
    Pass R, Duliege AM, Sekulovich R, Boppana S, Hirabayashi S, Britt WJ, Burke RL (1997) Antibody response to a fourth dose of CMV gB vaccine in healthy adults. Abstract 157. Sixth International Cytomegalovirus Workshop. March 7–9: Perdido Beach, ALGoogle Scholar
  41. 41.
    Plotkin SA (1999) Cytomegalovirus. In: Plotkin SA, Orenstein WA (eds) Vaccines. Saunders, Philadelphia, pp 903–908Google Scholar
  42. 42.
    Plotkin SA, Cadoz M, Meignier B, Meric C, Leroy 0, Excler JL, Tartaglia J, Paoletti E, Gonczol E, Chappuis G (1995) The safety and use of canarypox vectored vaccines. Dev Biol Stand 84: 165–170PubMedGoogle Scholar
  43. 43.
    Plotkin SA, Eagle H, Hayflick L, Ikic D, Koprowski H, Perkins F (1969) Serially cultured animal cells for the preparation of viral vaccines. Science 165: 1282CrossRefGoogle Scholar
  44. 44.
    Plotkin SA, Farquhar J, Horberger E (1976) Clinical trials of immunization with the Towne 125 strain of human cytomegalovirus. J Infect Dis 134: 470–475PubMedCrossRefGoogle Scholar
  45. 45.
    Plotkin SA, Furukawa T, Zygraich N, Huygelen C (1975) Candidate cytomegalovirus strain for human vaccination. Infect Immun 12: 521–527PubMedGoogle Scholar
  46. 46.
    Plotkin SA, Higgins R, Kurtz JB (1994) Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 58: 1176–1178PubMedGoogle Scholar
  47. 47.
    Plotkin SA, Huang ES (1985) Cytomegalovirus vaccine virus (Towne strain) does not induce latency. J Infect Dis 152: 395–397PubMedCrossRefGoogle Scholar
  48. 48.
    Plotkin SA, Smiley ML, Friedman HM, Starr SE, Fleisher GR, Wlodaver C, Dafoe DC, Friedman AD, Grossman RA, Barker CF (1984) Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants. Lancet 1: 528–530PubMedCrossRefGoogle Scholar
  49. 49.
    Plotkin SA, Starr SE, Friedman HM, Brayman K, Harris S, Jackson S, Tustin NB, Grossman R, Dafoe D, Barker C (1991) Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann Intern Med 114: 525–531PubMedGoogle Scholar
  50. 50.
    Plotkin SA, Starr SE, Friedman HM, Gonczol E, Weibel RE (1989) Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. J Infect Dis 159: 860–865PubMedCrossRefGoogle Scholar
  51. 51.
    Plotkin SA, Starr SE, Friedman HM, Gonczol E, Brayman K (1990) Vaccines for the prevention of human cytomegalovirus infection. Rev Infect Dis [Suppl] 7: S827—S838CrossRefGoogle Scholar
  52. 52.
    Porath A, McNutt RA, Smiley LM, Weigle KA (1990) Effectiveness and cost benefit of a proposed live cytomegalovirus vaccine in the prevention of congenital disease. Rev Infect Dis 12: 31–40PubMedCrossRefGoogle Scholar
  53. 53.
    Qadri I, Navarro D, Paz P, Pereira L (1992) Assembly of conformation-dependent neutralizing domains on glycoprotein B of human cytomegalovirus. J Gen Virol 73: 2913–2921PubMedCrossRefGoogle Scholar
  54. 54.
    Quinnan GV Jr, Delery MRA, Frederick WR, Epstein JS, Manischewitz JF, Jackson L, Ramsey KM, Mittal K, Plotkin SA (1984) Comparative virulence and immunogenicity of the Towne strain and a nonattenuated strain of cytomegalovirus. Ann Intern Med 101: 478–483PubMedGoogle Scholar
  55. 55.
    Rosenthal S, Stanberry LR, Biro FM, Slaoui M, Francotte M, Koutsoukos M, Hayes M, Bernstein DI (1997) Seroprevalence of Herpes simplex virus types 1 and 2 and cytomegalovirus in adolescents. Clin Infect Dis 24: 135–139PubMedCrossRefGoogle Scholar
  56. 56.
    Rasmussen L, Morris S, Wolitz R, Dowling A, Fessell J, Holodniy M, Merigan TC (1994) Deficiency in antibody response to human cytomegalovirus glycoprotein gH in human immunodeficiency virus-infected patients at risk for cytomegalovirus retinitis. J Infect Dis 170: 673–677PubMedCrossRefGoogle Scholar
  57. 57.
    Sinzger G, Jahn G (1996) Human cytomegalovirus cell tropism and pathogenesis. Inter-virology 39: 302–319Google Scholar
  58. 58.
    Smiley ML, Wlodaver CG, Grossman RA, Barker CF, Perloff LJ, Tustin NB, Starr SE, Plotkin SA, Friedman HM (1985) The role of pretransplant immunity in protection. Transplantation 40: 157–161PubMedCrossRefGoogle Scholar
  59. 59.
    Spaete RR (1991) A recombinant subunit vaccine approach to HCMV vaccine development. Transplant Proc 23: 90–96PubMedGoogle Scholar
  60. 60.
    Stagno S, Reynolds DW, Huang ES (1977) Congenital cytomegalovirus infection. N Engl J Med 296: 1254–1258PubMedCrossRefGoogle Scholar
  61. 61.
    Sutter G, Wyatt LS, Foley P, Bennink JR, Moss B (1994) A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12: 1032–1040PubMedCrossRefGoogle Scholar
  62. 62.
    Suwansirikul S, Rao N, Dowling IN, Ho M (1977) Primary and secondary cytomegalovirus infection. Arch Intern Med 137: 1036–1029CrossRefGoogle Scholar
  63. 63.
    Taylor J, Meignier B, Tartaglia J, Languet B, VanderHoeven J, Franchini G, Trimarchi C, Paoletti E (1995) Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine 13: 539–549PubMedCrossRefGoogle Scholar
  64. 64.
    Urban M, Klein M, Britt WJ, Hassfurther E, Mach M (1996) Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. J Gen Virol 77: 1537–1547PubMedCrossRefGoogle Scholar
  65. 65.
    Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A (1993) Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259: 1745–1749PubMedCrossRefGoogle Scholar
  66. 66.
    Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR (1982) Reconstruction of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 307: 7–13CrossRefGoogle Scholar
  67. 67.
    Wang TB, Adler SP, Hempfling S, Burke RL, Duliege AM, Starr SE, Plotkin SA (1996) Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines. J Infect Dis 174: 387–392PubMedCrossRefGoogle Scholar
  68. 68.
    Wills MR, Carmichael AJ, Mynard K, Jin X, Weekes MP, Plachter B, Sissons JG (1996) The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 70: 7569–7579PubMedGoogle Scholar
  69. 69.
    Wolff TA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL (1990) Direct gene transfer into mouse muscle in vivo. Science 247: 1465–1468PubMedCrossRefGoogle Scholar
  70. 70.
    Yamane Y, Furukawa T, Plotkin SA (1983) Supernatant virus release as a differentiating marker between low passage and vaccine strains of human cytomegalovirus. Vaccine 1: 25CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2001

Authors and Affiliations

  • S. A. Plotkin
    • 1
  1. 1.Wistar InstituteUniversity of Pennsylvania Emeritus ProfessorDoylestownUSA

Personalised recommendations